Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Lineage Cell Therapeutics completes enrollment in Phase 1/2a dry AMD trial

Lineage Cell Therapeutics (NASDAQ:LCTX) completed enrollment in its Phase 1/2a trial evaluating OpRegen for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy. OpRegen is injected into...

November 11, 2020

Markets

SVB Leerink starts Opthea at OP; PT $33

SVB Leerink launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $33 price target. The stock closed at $13.19 on Nov. 10. “The basis for our recommendation and valuation is our forecast for revenue...

November 11, 2020

Developments

IntelGenx receives U.S. patent for novel oral film dosage technology

IntelGenx (TSXV:IGX; OTCQB:IGXT) received a patent from the U.S. Patent and Trademark Office, covering a novel oral film dosage technology platform for modulating the absorption profile of a sublingually- or buccally...

November 11, 2020

Developments

Five Prime bemarituzumab meets all efficacy endpoints in Phase 2 gastric cancer trial

Five Prime Therapeutics (NASDAQ:FPRX) reported positive topline results from its Phase 2 trial evaluating bemarituzumab, in combination with chemotherapy, in patients with fibroblast growth factor receptor 2b-positive...

November 10, 2020

Developments

Lumos Pharma initiates Phase 2b pediatric growth hormone deficiency study

Lumos Pharma (NASDAQ:LUMO) launched a Phase 2b trial evaluating LUM-201 for the treatment of pediatric growth hormone deficiency (PGHD). PGHD is typically caused by the pituitary gland’s inability to make sufficient...

November 10, 2020

Markets

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...

November 10, 2020

Markets

HCW ups PDS Biotechnology to buy; PT $6

H.C. Wainwright upgraded PDS Biotechnology (NASDAQ:PDSB) to “buy” from “neutral” with a price target of $6. The stock closed at $2.04 on Nov. 9. In March 2020, HCW downgraded PDS based on dilution, significantly reduced...

November 10, 2020

Markets

Brookline starts Syros Pharma at buy; PT $19

Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...

November 10, 2020

Developments

Hepion completes first cohort enrollment in Phase 2 trial of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) enrolled the last patient in the 75 mg cohort of its Phase 2 ‘AMBITION’ clinical trial evaluating CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “We are pleased to...

November 10, 2020

Developments

Monopar Therapeutics gets new patents for Validive

Monopar Therapeutics (NASDAQ:MNPR) received additional patents for its Phase 2b/3 clinical-stage candidate, Validive. Monopar is developing Validive for the prevention of chemoradiation-induced severe oral mucositis in...

November 9, 2020

Developments

Corbus Pharma updates Phase 3 systemic sclerosis study results

Corbus Pharmaceuticals (NASDAQ:CRBP) updated data from its Phase 3 study of lenabasum for the treatment of systemic sclerosis. Systemic sclerosis is an autoimmune disease characterized by inflammation and fibrosis...

November 9, 2020

Developments

Entera Bio completes enrollment in Phase 2 osteoporosis trial

Entera Bio (NASDAQ:ENTX) completed enrollment in its Phase 2 trial evaluating EB613 for the treatment of osteoporosis. EB613 is an orally delivered human parathyroid hormone designed to build bone in osteoporosis...

November 9, 2020

Subscribe